 Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC LAOSCC. Although the treatment could provide prompt local control, but it is also associated with high incidence of distant failure. Systemic chemotherapy given either before neoadjuvant or after adjuvant definitive local treatment has been extensively evaluated to improve the clinical outcome in LAOSCC. Regimens of taxanecisplatin-based combinations have been shown to improve the treatment outcome of patients with locally advanced head and neck squamous cell carcinoma HNSCC in neoadjuvant setting. Recently, cetuximab Erbitux, a monoclonal antibody against epidermal growth factor receptor EGFR, has also been proven to be an efficient agent for advanced andor refractory HNSCC with acceptable toxicity profiles. In current study, we shall evaluate the feasibility, efficacy and safety of a triplet bio-chemotherapy consisting of cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bio-radiotherapy CBRT in patients with LAOSCC. 